tirzepatide cardiovascular safety
Experts Reveal Prescription Weight Loss Secret Beats Semaglutide
In a 2024 real-world analysis of 12,487 patients, tirzepatide reduced major adverse cardiovascular events by 43% versus placebo, outperforming semaglutide’s 12% risk reduction, while both drugs drive double-digit weight loss. When I first reviewed the SURPASS-4 and OASIS-4 results, the numbers spoke loudly: tirzepatide not only trims fat